2 terminated. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Terminated 2 |
| Phase 1 | 1 | Terminated 1 |
Follow Viron Therapeutics Inc: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Treatment of Elderly Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic (MD) Syndrome With Laromustine and Infusional Cytarabine Laromustine (VNP40101M) and Ara-C - Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) | Phase 1 / Phase 2 | Terminated | Viron Therapeutics Inc | 25 | 2008-03-01 | 2019-01-28 |
| Serp-1 for the Treatment of Acute Coronary Syndrome Serine proteinase-1 (Serp-1) - Unstable Angina, Coronary Atherosclerosis | Phase 2 | Terminated | Viron Therapeutics Inc | 72 | 2005-10-01 | 2009-02-06 |
Acute Coronary Syndrome (1) · Angina, Unstable (1) · Coronary Artery Disease (1) · Coronary Restenosis (1) · Leukemia (1) · Leukemia, Myeloid, Acute (1) · Myelodysplastic Syndromes (1)
Cytarabine (1) · laromustine (1)
United States (2) · Canada (1)
Alexandra Lucas, MD (1) · Jean-Claude Tardif, MD (1)